NSE · MANKIND
Mankind Pharma Limited
Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.
Market cap rank
#104
of 5,084 stocks
🏆 New peak
▲ 211W
Peak #104 · 29 Sep 2026
Operating in Healthcare, Mankind Pharma Limited carries a steep earnings multiple that prices in strong future growth, remains firmly promoter-controlled, with promoters holding 73%, and is growing revenue at a solid clip.
Market Cap
105,108.50 Cr
P/E Ratio
54.91
P/B Ratio
6.34
ROE
11.70%
ROCE
14.32%
Dividend Yield
—
52W High
—
52W Low
—
Quarterly financials
| Metric | Q1 2026-27 | Q4 2025-26 | Q3 2025-26 | Q2 2025-26 |
|---|---|---|---|---|
| Revenue | 4,030.59 Cr | 3,442.93 Cr | 3,567.20 Cr | 3,697.16 Cr |
| Net Profit | 574.09 Cr | 559.42 Cr | 413.88 Cr | 520.18 Cr |
| EPS | 13.76 | 13.44 | 9.90 | 12.39 |
| Operating Profit | 875.49 Cr | 821.09 Cr | 769.58 Cr | 791.38 Cr |
Shareholding pattern
Promoter
72.63%
Public
27.37%
PUBLIC BREAKDOWN
FII
9.45%
DII
15.39%
MF (within DII)
10.87%
Individuals
1.34%
Mutual fund holdings
₹10,994.75
Cr total
210
Schemes
31
Fund Houses
₹10,994.75 Cr
Total Exposure
Nippon India Mutual Fund₹2,389.85 Cr (21.7%)
SBI Mutual Fund₹1,496.69 Cr (13.6%)
Aditya Birla Sun Life Mutual Fund₹1,114.31 Cr (10.1%)
HDFC Mutual Fund₹716.90 Cr (6.5%)
Franklin Templeton Mutual Fund₹694.85 Cr (6.3%)
Others₹4,582.15 Cr (41.7%)
Recent corporate actions
| Ex-Date | Type | Details |
|---|---|---|
| 08 Aug 2025 | Dividend | Interim Dividend - Re 1 Per Share |
Need this data in your app?
Full price history, technical indicators, and every field above via one REST API call.